Studies To Examine Potential Tolerability Differences between the 5-HT2C Receptor Selective Agonists Lorcaserin and CP-809101

Author:

Higgins Guy A.12ORCID,Silenieks Leonardo B.1,Patrick Amy1,De Lannoy Ines A. M.1,Fletcher Paul J.34,Parker Linda A.5,MacLusky Neil J.6,Sullivan Laura C.7,Chavera Teresa A.7,Berg Kelly A.7

Affiliation:

1. InterVivo Solutions Inc., 120 Carlton Street, Toronto, Ontario M5A 4K2, Canada

2. Department of Pharmacology & Toxicology, University of Toronto, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada

3. Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1L8, Canada

4. Department of Psychology & Psychiatry, University of Toronto, 100 St. George Street, Toronto, Ontario M5S 3G3, Canada

5. Department of Psychology, University of Guelph, 50 Stone Road East, Guelph, Ontario N1G 2W1, Canada

6. Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario N1G 2W1, Canada

7. Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States

Funder

Canadian Institutes of Health Research

University of Texas Health Science Center at San Antonio

Natural Sciences and Engineering Research Council of Canada

InterVivo Solutions Inc.

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Reference64 articles.

1. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs

2. Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials

3. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists

4. Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial

5. FDA Briefing Document: NDA 22-529; Lorcaserinhydrochloride. Advisory committee meeting May 10th (2012. Sponsor: Arena Pharmaceuticals.http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303198.pdf.

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3